MMP9 and myeloid sarcoma: In accordance with our results, clinical studies demonstrated a significant elevation in MMP-9 and MMP-2 serum levels in the RRMS, primary progressive form (PP-MS) and secondary progressive MS (SPMS) groups compared to healthy controls [11, 12, 24].